Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Oxaborole backup

Human African Trypanosomiasis Research

  • Target disease: HAT
  • Partners: Anacor, USA; SCYNEXIS, USA; Pace University, USA; WuXi AppTec, China
  • Leadership: Discovery and Pre-clinical Director: Robert Don; Head of Drug Discovery: Charles Mowbray; Project Manager: Ivan Scandale; Project Coordinators: Delphine Launay, Stéphanie Braillard
  • Project start: April 2007
  • Funding: Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland

  • Objective: Profile potential backup candidates for SCYX-7158 for the treatment of HAT

The prototype oxaborole SCYX-7158 is progressing through Phase I clinical trials. A range of structurally diverse oxaboroles with good activity against T. brucei were profiled in an animal pharmacokinetic (PK) study and several promising candidates with shorter half-lives than SCYX-7158 were identified. In depth DMPK and in vitro parasitology profiling narrowed the selection to SCYX-8210 and SCYX-0682, which may offer good backups to SCYX-7158 if needed. SCYX-7158 continues to make good progress in Phase I clinical trials, so at present there is no urgent need for a backup compound. Thus, only limited further development of SCYX-8210 and SCYX-0682 will be performed in 2013.

Last update: October 2013

Tags: HAT – Sleeping Sickness
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License